The abstract is read at the publisher; the summary is JClub's.
A second-generation anti-CD94 CAR-T therapy shows potent, selective killing of CD94-positive cytotoxic T/NK-cell malignancies and completely eradicates NK-cell leukemia xenografts.
- Why it matters: Pan–B-cell CAR-T works well, but targeting T-cell lymphomas risks prolonged T-cell aplasia, so safer antigens with restricted normal-tissue expression are needed.
- What they did: The team built CD94 CAR-T cells using a specific, high-affinity anti-CD94 monoclonal antibody and tested cytotoxicity in vitro and in vivo in xenograft models, adding a truncated BCMA safety switch.
- The result: In vivo, CD94 CAR-T completely eradicated NK-cell leukemia xenografts and patient-derived xenografts of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma, and a BCMA switch enabled rapid CAR-T elimination.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.